Q3 2021 13F Holders as of 30 Sep 2021
-
Type / Class
-
Equity / Common Stock
-
Shares outstanding
-
74,361,296
-
Number of holders
-
55
-
Total 13F shares, excl. options
-
28,180,241
-
Shares change
-
+4,492,111
-
Total reported value, excl. options
-
$136,388,000
-
Value change
-
+$22,907,893
-
Put/Call ratio
-
40.69%
-
Number of buys
-
30
-
Number of sells
-
-26
-
Price
-
$4.84
Significant Holders of Corvus Pharmaceuticals, Inc. - Common Stock (CRVS) as of Q3 2021
75 filings reported holding CRVS - Corvus Pharmaceuticals, Inc. - Common Stock as of Q3 2021.
Corvus Pharmaceuticals, Inc. - Common Stock (CRVS) has 55 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 28,180,241 shares
of 74,361,296 outstanding shares and own 37.9% of the company stock.
Largest 10 shareholders include ORBIMED ADVISORS LLC (6,943,654 shares), TANG CAPITAL MANAGEMENT LLC (3,749,379 shares), VR Adviser, LLC (3,427,461 shares), ADAMS STREET PARTNERS LLC (3,275,616 shares), EcoR1 Capital, LLC (2,081,077 shares), BVF INC/IL (1,370,947 shares), VANGUARD GROUP INC (1,203,363 shares), Ikarian Capital, LLC (757,545 shares), PURA VIDA INVESTMENTS, LLC (734,268 shares), and RENAISSANCE TECHNOLOGIES LLC (614,370 shares).
This table shows the top 55 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.